文献速递血脂与心血管预防

靶向PCSK9的单疗程CRISPR碱基编辑疗法在非人灵长类和小鼠模型中的有效性与安全性

Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models.
PubMed 文献 · Circulation · 2022-10-31

VERVE-101是一种研究性体内CRISPR碱基编辑药物,旨在改变PCSK9基因的单个DNA碱基,永久关闭肝脏蛋白生产,从而持久降低低密度脂蛋白胆固醇。在食蟹猴中单次静脉输注VERVE-101后,0.75和1.5 mg/kg剂量组第14天肝脏PCSK9编辑效率分别为46%和70%,达476天的PCSK9平均降低67%和83%,LDL-C降低49%和69%。肝酶短暂升高后第14天完全恢复,未见生殖系编辑证据,支持启动首次人体试验。

要点

  • VERVE-101单次输注在猴中实现PCSK9编辑效率46%-70%,LDL-C降低49%-69%。
  • 降脂效应持久达476天,肝酶短暂升高后第14天恢复,无胆红素变化。
  • 精子及小鼠后代中未检测到PCSK9编辑,未见生殖系编辑证据。

核心结论

  • VERVE-101在非人灵长类中耐受良好,单次给药后PCSK9蛋白降低83%、LDL-C降低69%,效应持久达476天。
  • 结果支持在杂合子家族性高胆固醇血症和动脉粥样硬化性心血管疾病患者中启动首次人体临床试验。

研究设计与样本

  • 食蟹猴单次静脉输注载体对照(n=10)或VERVE-101 0.75 mg/kg(n=4)或1.5 mg/kg(n=22),随访至476天。
  • 生殖系编辑评估包括:性成熟雄性非人灵长类给药后精子样本测序,以及雌性小鼠接受鼠源替代物VERVE-101mu后子代基因分型(n=436)。

主要发现

  • 给药后14天肝活检显示,0.75和1.5 mg/kg组平均PCSK9编辑效率分别为46%和70%。
  • 第28天至476天时间加权平均变化显示,0.75和1.5 mg/kg组血PCSK9平均降低67%和83%,LDL-C降低49%和69%。
  • 输注后丙氨酸氨基转移酶和天冬氨酸氨基转移酶短暂升高,第14天完全恢复,总胆红素无变化。
  • 给药1年后尸检亚组猴的肝脏和其他器官宏观及组织病理学评估未见VERVE-101相关发现。
  • 雄性非人灵长类给药后精子样本未显示PCSK9编辑证据;436只接受饱和剂量VERVE-101mu的雌性小鼠子代中0只传递PCSK9编辑。

临床怎么用

  • VERVE-101作为单疗程碱基编辑疗法,可能为杂合子家族性高胆固醇血症和动脉粥样硬化性心血管疾病患者提供持久降LDL-C的新选择。
  • 临床应用中需监测输注后肝酶变化,但本研究中肝酶升高短暂且可完全恢复。

局限性

  • 研究仅限非人灵长类和小鼠模型,人类安全性和有效性尚待临床试验验证。
  • 生殖系编辑评估基于有限样本(雄性非人灵长类精子及小鼠子代),长期生殖系风险需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: VERVE-101 is an investigational in vivo CRISPR base-editing medicine designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic protein production, and thereby durably lower low-density lipoprotein cholesterol. We test the efficacy, durability, tolerability, and potential for germline editing of VERVE-101 in studies of nonhuman primates and a murine F1 progeny study. METHODS: Cynomolgus monkeys were given a single intravenous infusion of a vehicle control (n=10) or VERVE-101 at a dose of 0.75 mg/kg (n=4) or 1.5 mg/kg (n=22) with subsequent follow-up up to 476 days. Two studies assessed the potential for germline editing, including sequencing sperm samples from sexually mature male nonhuman primates treated with VERVE-101 and genotyping offspring from female mice treated with the murine surrogate of VERVE-101 (VERVE-101mu). RESULTS: Liver biopsies 14 days after dosing noted mean PCSK9 editing of 46% and 70% in monkeys treated with VERVE-101 at 0.75 and 1.5 mg/kg, respectively. This translated into mean reductions in blood PCSK9 (proprotein convertase subtilisin/kexin type 9) of 67% and 83% and reductions of low-density lipoprotein cholesterol of 49% and 69% at the 0.75 and 1.5 mg/kg doses, respectively, assessed as time-weighted average change from baseline between day 28 and up to 476 days after dosing. Liver safety monitoring noted a transient rise in alanine aminotransferase and aspartate aminotransferase concentrations after infusion that fully resolved by day 14 with no accompanying change in total bilirubin. In a subset of monkeys necropsied 1 year after dosing, no findings related to VERVE-101 were identified on macroscopic and histopathologic assessment of the liver and other organs. In the study to assess potential germline editing of male nonhuman primates, sperm samples collected after VERVE-101 dosing showed no evidence of PCSK9 editing. Among 436 offspring of female mice treated with a saturating dose of VERVE-101mu, the PCSK9 edit was transmitted in 0 of 436 animals. CONCLUSIONS: VERVE-101 was well tolerated in nonhuman primates and led to 83% lower blood PCSK9 protein and 69% lower low-density lipoprotein cholesterol with durable effects up to 476 days after dosing. These results have supported the initiation of a first-in-human clinical trial in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lee RG, Mazzola AM, Braun MC, et al. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models. Circulation. 2022. PMID: 36314243. doi:10.1161/CIRCULATIONAHA.122.062132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。